.png&w=384&q=75)
Brexpiprazole is an atypical antipsychotic indicated for:
The mechanism of action of brexpiprazole in the treatment of major depressive disorder or schizophrenia is unknown. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors.
Adjunctive Treatment Of Major Depressive Disorder:
The recommended starting dosage for REXULTI as adjunctive treatment is 0.5 mg or 1 mg once daily, taken orally with or without food.
Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient’s clinical response and tolerability. The maximum recommended daily dosage is 3 mg. Periodically reassess to determine the continued need and appropriate dosage for treatment.
Treatment Of Schizophrenia:
The recommended starting dosage for REXULTI is 1 mg once daily on Days 1 to 4, taken orally with or without food
Common side effects of brexpiprazole may include:
Adequate and well-controlled studies have not been conducted with Brexpiprazole in pregnant women to inform drugassociated risks. However, neonates whose mothers are exposed to antipsychotic drugs, like Brexpiprazole during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms.Lactation studies have not been conducted to assess the presence of brexpiprazole in human milk, the effects of brexpiprazole on the breastfed infant, or the effects of brexpiprazole on milk production. Brexpiprazole is present in rat milk.
Store at 20°C t o 25°C